306 related articles for article (PubMed ID: 11809688)
1. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.
Hansen-Petrik MB; McEntee MF; Jull B; Shi H; Zemel MB; Whelan J
Cancer Res; 2002 Jan; 62(2):403-8. PubMed ID: 11809688
[TBL] [Abstract][Full Text] [Related]
2. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis.
Chiu CH; McEntee MF; Whelan J
Cancer Res; 1997 Oct; 57(19):4267-73. PubMed ID: 9331087
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.
Boolbol SK; Dannenberg AJ; Chadburn A; Martucci C; Guo XJ; Ramonetti JT; Abreu-Goris M; Newmark HL; Lipkin ML; DeCosse JJ; Bertagnolli MM
Cancer Res; 1996 Jun; 56(11):2556-60. PubMed ID: 8653697
[TBL] [Abstract][Full Text] [Related]
4. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
5. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
6. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
[TBL] [Abstract][Full Text] [Related]
8. Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice.
Chiu CH; McEntee MF; Whelan J
Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):269-75. PubMed ID: 10883057
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Piazza GA; Rahm AK; Finn TS; Fryer BH; Li H; Stoumen AL; Pamukcu R; Ahnen DJ
Cancer Res; 1997 Jun; 57(12):2452-9. PubMed ID: 9192825
[TBL] [Abstract][Full Text] [Related]
10. The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors.
Cahlin C; Gelin J; Andersson M; Lönnroth C; Lundholm K
Int J Oncol; 2005 Oct; 27(4):913-23. PubMed ID: 16142306
[TBL] [Abstract][Full Text] [Related]
11. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis.
Tanaka K; Suemasu S; Ishihara T; Tasaka Y; Arai Y; Mizushima T
Eur J Pharmacol; 2009 Jan; 603(1-3):120-32. PubMed ID: 19101538
[TBL] [Abstract][Full Text] [Related]
14. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice.
Sonoshita M; Takaku K; Sasaki N; Sugimoto Y; Ushikubi F; Narumiya S; Oshima M; Taketo MM
Nat Med; 2001 Sep; 7(9):1048-51. PubMed ID: 11533709
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2-derived prostaglandin e2 protects mouse embryonic stem cells from apoptosis.
Liou JY; Ellent DP; Lee S; Goldsby J; Ko BS; Matijevic N; Huang JC; Wu KK
Stem Cells; 2007 May; 25(5):1096-103. PubMed ID: 17234991
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E prevents indomethacin-induced gastric and intestinal damage through different EP receptor subtypes.
Kunikata T; Araki H; Takeeda M; Kato S; Takeuchi K
J Physiol Paris; 2001; 95(1-6):157-63. PubMed ID: 11595431
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice.
Axelsson H; Lönnroth C; Wang W; Svanberg E; Lundholm K
Angiogenesis; 2005; 8(4):339-48. PubMed ID: 16400521
[TBL] [Abstract][Full Text] [Related]
18. Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac.
Mahmoud NN; Bilinski RT; Churchill MR; Edelmann W; Kucherlapati R; Bertagnolli MM
Cancer Res; 1999 Jan; 59(2):353-9. PubMed ID: 9927046
[TBL] [Abstract][Full Text] [Related]
19. PGE(2) receptors and their intracellular mechanisms in rabbit small intestine.
Grasa L; Arruebo MP; Plaza MA; Murillo MD
Prostaglandins Other Lipid Mediat; 2006 May; 79(3-4):206-17. PubMed ID: 16647635
[TBL] [Abstract][Full Text] [Related]
20. PGE(2) induces COX-2 expression in podocytes via the EP(4) receptor through a PKA-independent mechanism.
Faour WH; Gomi K; Kennedy CR
Cell Signal; 2008 Nov; 20(11):2156-64. PubMed ID: 18762248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
